Hamburger Zentrum fuer Kinder- und Jugendrheumatologie
- Address
- Dehnhaide 120, Barmbek-Süd, 22081 Hamburg, Germany
Hamburger Zentrum für Kinder- und Jugendrheumatologie
The Hamburger Zentrum für Kinder- und Jugendrheumatologie is a specialized pediatric rheumatology center dedicated to advancing the treatment of autoimmune and inflammatory joint diseases in children and adolescents. The center focuses on evaluating novel therapeutic interventions for young patients who have not responded adequately to conventional treatment approaches.
- Juvenile Psoriatic Arthritis (jPsA) treatment optimization with biologic therapies
- Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA) pharmacokinetic studies
- Safety and efficacy assessment of targeted immunomodulatory agents in pediatric populations
The center's clinical research program emphasizes personalized medicine approaches for children aged 5 to 18 years with inadequate response to methotrexate (MTX) or other conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Through comprehensive pharmacokinetic evaluations and long-term safety monitoring, the center contributes essential data to optimize dosing strategies and treatment outcomes for juvenile inflammatory arthritis conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hamburger Zentrum fuer Kinder- und Jugendrheumatologie
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Dose-Finding Study of Sarilumab in Pediatric Patients with Systemic Juvenile Idiopathic Arthritis | Sanofi-Aventis Recherche & Developpement | Phase II | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adalimumab | 2 | Unknown | 2021-02-22 | 2024-04-29 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.